Have moderate or severe cardiovascular disease:Xx_NEWLINE_xXSignificant history of cardiovascular diseaseXx_NEWLINE_xXPatients with clinically relevant medical history, including autoimmune disease, cardiovascular disease, hepatic disease or bleeding disordersXx_NEWLINE_xXUncontrolled or significant cardiovascular diseaseXx_NEWLINE_xXEvidence of clinically significant cardiovascular and respiratory conditionsXx_NEWLINE_xXSignificant cardiovascular disease;Xx_NEWLINE_xXSignificant cardiovascular disease or active pulmonary diseaseXx_NEWLINE_xXCardiovascular Risks as outlined in the protocol.Xx_NEWLINE_xXClinically significant cardiovascular diseaseXx_NEWLINE_xXEvidence of significant uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results, including significant liver disease, cardiovascular disease, and presence of an abnormal electrocardiogram (ECG)Xx_NEWLINE_xXPatients with pre-existing history of or known cardiovascular riskXx_NEWLINE_xXSignificant cardiovascular diseaseXx_NEWLINE_xXSignificant cardiovascular diseaseXx_NEWLINE_xXAny of the following cardiovascular criteria:Xx_NEWLINE_xXSubjects with clinically significant cardiovascular disease, including:Xx_NEWLINE_xXSignificant cardiovascular/cerebrovascular disease within 6 months prior to Day 1 of study drug administrationXx_NEWLINE_xXSignificant cardiovascular diseaseXx_NEWLINE_xXHas a history of or current uncontrolled cardiovascular diseaseXx_NEWLINE_xXHistory or evidence of cardiovascular riskXx_NEWLINE_xXCurrent severe, uncontrolled systemic disease (for example [e.g.] clinically significant cardiovascular, pulmonary, or metabolic disease)Xx_NEWLINE_xXCurrent severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, or metabolic disease) or intercurrent illness that could interfere with per-protocol evaluations.Xx_NEWLINE_xXSignificant cardiovascular disease.Xx_NEWLINE_xXHave moderate or severe cardiovascular disease.Xx_NEWLINE_xXClinically significant cardiovascular diseaseXx_NEWLINE_xXSignificant cardiovascular diseaseXx_NEWLINE_xXAny significant cardiovascular events within 6 months prior to study entryXx_NEWLINE_xXClinically significant cardiovascular disease, history of myocardial infarction within the last 6 months, or evidence of QTc interval prolongation at screeningXx_NEWLINE_xXHistory of a significant cardiovascular illnessXx_NEWLINE_xXSignificant active cardiovascular or pulmonary disease including:Xx_NEWLINE_xXHas had any major cardiovascular event within 6 months prior to study drug administrationXx_NEWLINE_xXSignificant cardiovascular diseaseXx_NEWLINE_xXCurrent severe, uncontrolled systemic disease (including, but not limited to, clinically significant cardiovascular, pulmonary, or renal disease) other than cancerXx_NEWLINE_xXUncontrolled or significant cardiovascular diseasesXx_NEWLINE_xXHistory or evidence of cardiovascular riskXx_NEWLINE_xXUncontrolled or significant cardiovascular diseaseXx_NEWLINE_xXSubjects with significant or uncontrolled cardiovascular diseaseXx_NEWLINE_xXSignificant cardiovascular diseaseXx_NEWLINE_xXClinically significant cardiovascular disease or conditionXx_NEWLINE_xXNon-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude any of the study drugsXx_NEWLINE_xXPatients with clinically significant cardiovascular disease, thromboembolic disease, or significant risk of bleeding.Xx_NEWLINE_xXUncontrolled or significant cardiovascular diseaseXx_NEWLINE_xXSignificant cardiovascular disease or ECG abnormalities.Xx_NEWLINE_xXCurrently active clinically significant cardiovascular disease or history of myocardial infarction within 6 months of first doseXx_NEWLINE_xXClinically significant cardiovascular or pulmonary diseaseXx_NEWLINE_xXHistory of uncontrolled cardiovascular disease includingXx_NEWLINE_xXSignificant known cardiovascular impairment.Xx_NEWLINE_xXUncontrolled or significant cardiovascular disease.Xx_NEWLINE_xXPatients with uncontrolled or significant cardiovascular disease including, but not limited to, any of the following are ineligible:\r\n* Myocardial infarction or stroke/transient ischemic attack (TIA) within the 6 months prior to consent\r\n* Uncontrolled angina within the 3 months prior to consent\r\n* Any history of clinically significant arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes)\r\n* History of other clinically significant cardiovascular disease (i.e., cardiomyopathy, congestive heart failure with New York Heart Association [NYHA] functional classification III-IV, myocarditis and pericarditis, significant pericardial effusion, significant coronary stent occlusion, deep venous thrombosis, etc.)\r\n* Cardiovascular disease-related requirement for daily supplemental oxygenXx_NEWLINE_xXHistory of clinically significant cardiovascular diseaseXx_NEWLINE_xXClinically significant cardiovascular disease.Xx_NEWLINE_xXSignificant cardiovascular disease, within 3 months prior to randomisation, unstable arrhythmias, or unstable anginaXx_NEWLINE_xXClinically significant cardiovascular disease or conditionXx_NEWLINE_xXCurrent severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, or metabolic disease)Xx_NEWLINE_xXHistory of clinically significant cardiovascular disease;Xx_NEWLINE_xXUncontrolled or significant cardiovascular diseaseXx_NEWLINE_xXAny known uncontrolled cardiovascular disease;Xx_NEWLINE_xXClinically significant cardiovascular disease.Xx_NEWLINE_xXClinically significant cardiovascular diseaseXx_NEWLINE_xXEvidence of significant, uncontrolled, concomitant diseases that could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease or pulmonary diseaseXx_NEWLINE_xXEvidence of significant cardiovascular conditions as specified below:Xx_NEWLINE_xXUncontrolled or significant cardiovascular diseaseXx_NEWLINE_xXHistory of cardiovascular diseaseXx_NEWLINE_xXCardiovascular disordersXx_NEWLINE_xXSignificant active cardiovascular or pulmonary disease before administration of the first dose of study drug, including:Xx_NEWLINE_xXHave moderate or severe cardiovascular disease.Xx_NEWLINE_xXPatients with a significant cardiovascular disease or condition, including:Xx_NEWLINE_xXHave moderate or severe cardiovascular disease.Xx_NEWLINE_xXHave moderate or severe cardiovascular disease:Xx_NEWLINE_xXPatients with a significant cardiovascular disease or condition, including:Xx_NEWLINE_xXClinically significant cardiovascular disease.Xx_NEWLINE_xXMedically significant cardiac event or unstable cardiovascular function defined as:Xx_NEWLINE_xXHave clinically significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:Xx_NEWLINE_xXClinically significant cardiovascular diseaseXx_NEWLINE_xXRecent (one year) history or symptoms of cardiovascular disease (NYHA Class 2, 3, or 4), particularly coronary artery disease, arrhythmias or conduction defects with risk of cardiovascular instability, uncontrolled hypertension, clinically significant pericardial effusion, or congestive heart failureXx_NEWLINE_xXClinically significant cardiovascular disease including:Xx_NEWLINE_xXHave significant, uncontrolled, or active cardiovascular disease, including, but not restricted to:Xx_NEWLINE_xXCardiovascular Function: Adequate cardiovascular function in the opinion of the Investigator with no clinically significant uncontrolled cardiovascular disease.Xx_NEWLINE_xXSubject has significant cardiovascular disease, including:Xx_NEWLINE_xXUncontrolled cardiovascular history, defined as:Xx_NEWLINE_xXClinically significant cardiovascular disease or conditionXx_NEWLINE_xXHas cardiovascular risk factorsXx_NEWLINE_xXHistory or current condition of an uncontrolled cardiovascular disease including any of the following conditions:Xx_NEWLINE_xXSignificant cardiovascular disease, such asXx_NEWLINE_xXPredefined cardiovascular diseaseXx_NEWLINE_xXAcute cardiovascular disease in the previous 30 daysXx_NEWLINE_xXSignificant cardiovascular disease within 3 months prior to Day 1 of Cycle 1Xx_NEWLINE_xXSubjects who developed cardiovascular disease within 24 weeks prior to study entry, which is deemed to be clinically significant by the Investigator.Xx_NEWLINE_xXHas uncontrolled or significant cardiovascular diseaseXx_NEWLINE_xXKnown clinically significant cardiovascular disease or condition.Xx_NEWLINE_xXHave a significant electrocardiogram finding or cardiovascular diseaseXx_NEWLINE_xXNo known history of cardiovascular diseaseXx_NEWLINE_xXCurrently active, clinically significant cardiovascular disease or a history of myocardial infarction within 6 months prior to inclusionXx_NEWLINE_xXImpaired cardiovascular function or clinically significant cardiovascular disease including any of the following: symptomatic congestive heart failure, clinically significant cardiac arrhythmias and/or conduction abnormalities < 6 months prior to screening except for atrial fibrillation and paroxysmal supraventricular tachycardiaXx_NEWLINE_xXClinically significant, uncontrolled, cardiovascular disease.Xx_NEWLINE_xXHistory of clinically-significant cardiovascular disease.Xx_NEWLINE_xXAny evidence of severe or uncontrolled systemic disease such as clinically significant cardiovascular, pulmonary, hepatic, renal or metabolic diseaseXx_NEWLINE_xXSignificant cardiovascular diseaseXx_NEWLINE_xXUncontrolled or significant cardiovascular diseaseXx_NEWLINE_xXHistory of cardiovascular illness;Xx_NEWLINE_xXSignificant cardiovascular diseaseXx_NEWLINE_xXClinically significant cardiovascular diseaseXx_NEWLINE_xXClinically significant cardiovascular risk.Xx_NEWLINE_xXUncontrolled or significant cardiovascular diseaseXx_NEWLINE_xXClinically significant (i.e., active) cardiovascular diseaseXx_NEWLINE_xXSignificant cardiovascular disease.Xx_NEWLINE_xXSignificant cardiovascular disease within 6 months of screening.Xx_NEWLINE_xXSignificant cardiovascular disease within 6 months of screening.Xx_NEWLINE_xXSignificant cardiovascular diseaseXx_NEWLINE_xXPatients with pre-existing history of or known cardiovascular riskXx_NEWLINE_xXUncontrolled or significant cardiovascular diseaseXx_NEWLINE_xXSignificant cardiovascular diseaseXx_NEWLINE_xXEvidence of clinically significant disease (e.g., cardiovascular, respiratory, gastrointestinal, renal disease) that in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments.Xx_NEWLINE_xXUncontrolled or significant cardiovascular diseaseXx_NEWLINE_xXSignificant cardiovascular disease.Xx_NEWLINE_xXSignificant cardiovascular diseaseXx_NEWLINE_xXClinically significant cardiovascular diseaseXx_NEWLINE_xXHistory of specific cardiovascular abnormalities;Xx_NEWLINE_xXStable cardiovascular, pulmonary health statusXx_NEWLINE_xXHas a history of any of the following cardiovascular conditions within 12 months of randomization:Xx_NEWLINE_xXSubject has clinically significant cardiovascular disease.Xx_NEWLINE_xXClinically significant cardiovascular disease;Xx_NEWLINE_xXClinically symptomatic and uncontrolled cardiovascular diseaseXx_NEWLINE_xXSignificant cardiovascular disease (including congestive heart failure).Xx_NEWLINE_xXSignificant cardiovascular diseaseXx_NEWLINE_xXHave significant, uncontrolled, or active cardiovascular disease, as defined by the study protocol.Xx_NEWLINE_xXPatients with clinically significant cardiovascular disease.Xx_NEWLINE_xXHistory of autoimmune disease, significant pulmonary disease, or significant cardiovascular diseaseXx_NEWLINE_xXSignificant active cardiovascular or pulmonary disease including:Xx_NEWLINE_xXSignificant cardiovascular or liver diseaseXx_NEWLINE_xXSignificant history of cardiovascular diseaseXx_NEWLINE_xXPatients with clinically significant, uncontrolled cardiovascular diseaseXx_NEWLINE_xXHistory or presence of clinically relevant cardiovascular abnormalities as per investigator assessment.Xx_NEWLINE_xXHistory or evidence of cardiovascular risk including any of the following:Xx_NEWLINE_xXSignificant cardiovascular disease or significant pulmonary diseaseXx_NEWLINE_xXSignificant cardiovascular diseasesXx_NEWLINE_xXSignificant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, cardiovascular, or hepatic diseaseXx_NEWLINE_xXSerious cardiac or cardiovascular disease or conditionXx_NEWLINE_xXHave a history or current evidence of uncontrolled cardiovascular disease.Xx_NEWLINE_xXSignificant cardiovascular or pulmonary diseaseXx_NEWLINE_xXSubjects with clinically significant cardiovascular disease.Xx_NEWLINE_xXSubject has clinically significant cardiovascular disease including:Xx_NEWLINE_xXSubjects with clinically significant cardiovascular disease. This includes:Xx_NEWLINE_xXPatients taking aspirin for previously diagnosed cardiovascular diseaseXx_NEWLINE_xXPatient has uncontrolled or significant cardiovascular disease, including:Xx_NEWLINE_xXSignificant cardiovascular diseaseXx_NEWLINE_xXSignificant active cardiovascular or pulmonary disease at study entry ? History of arrhythmia requiring an implantable cardiac defibrillatorXx_NEWLINE_xXCurrently active, clinically significant cardiovascular disease.Xx_NEWLINE_xXCurrently active, clinically significant cardiovascular diseaseXx_NEWLINE_xXSignificant cardiovascular disease.Xx_NEWLINE_xXHistory or evidence of cardiovascular conditionXx_NEWLINE_xXSignificant cardiovascular diseaseXx_NEWLINE_xXClinically significant cardiovascular disease;Xx_NEWLINE_xXHave significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:Xx_NEWLINE_xXUncontrolled or significant cardiovascular disease, including:Xx_NEWLINE_xXHistory of any one or more of the following cardiovascular conditions within the past 6 months:Xx_NEWLINE_xXClinically significant cardiovascular diseaseXx_NEWLINE_xXA history of significant renal, neurologic, psychiatric, endocrine, metabolic, immunologic, cardiovascular or hepatic diseaseXx_NEWLINE_xXSevere cardiovascular or hepatic diseaseXx_NEWLINE_xXSignificant cardiovascular diseaseXx_NEWLINE_xXClinically significant cardiovascular diseaseXx_NEWLINE_xXEvidence of clinically significant disease (e.g., cardiovascular, respiratory, gastrointestinal, renal disease) that in the opinion of the investigator could affect the subject safety or interfere with the study assessmentsXx_NEWLINE_xXUncontrolled or significant cardiovascular diseaseXx_NEWLINE_xXClinically significant (that is, active) cardiovascular diseaseXx_NEWLINE_xXImpaired cardiovascular function or clinically significant cardiovascular diseasesXx_NEWLINE_xXCardiovascular conditions as defined in the protocolXx_NEWLINE_xXEvidence of current uncontrolled cardiovascular conditionsXx_NEWLINE_xXImpaired cardiovascular function or clinically significant cardiovascular diseases.Xx_NEWLINE_xXImpaired cardiovascular function or clinically significant cardiovascular diseasesXx_NEWLINE_xXHistory of significant renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, cardiovascular, or hepatic diseaseXx_NEWLINE_xXHistory or current evidence of cardiovascular risk.Xx_NEWLINE_xXClinical or radiographic evidence of central nervous system metastases or significant cardiovascular diseaseXx_NEWLINE_xXPatients must not have cardiovascular disease risk factors as defined below:Xx_NEWLINE_xXClinically relevant cardiovascular abnormalities as judged by the investigator.Xx_NEWLINE_xXEvidence of current uncontrolled cardiovascular conditions within the past 6 monthsXx_NEWLINE_xXHave significant or active cardiovascular diseaseXx_NEWLINE_xXHistory of clinically significant cardiovascular disease including.Xx_NEWLINE_xXCurrently active, clinically significant cardiovascular diseaseXx_NEWLINE_xXKnown active cardiovascular disease condition as specified in protocolXx_NEWLINE_xXSignificant cardiovascular disease including CHF, leptomeningeal disease, poorly controlled hypertension, or an MI within 6 months prior to dosing.Xx_NEWLINE_xXActive cardiovascular disease or significant history thereof.Xx_NEWLINE_xXSignificant cardiovascular disease.Xx_NEWLINE_xXClinically significant cardiovascular disease;Xx_NEWLINE_xXModerate or severe cardiovascular diseaseXx_NEWLINE_xXDONOR: Significant cardiovascular diseaseXx_NEWLINE_xXHistory of clinically significant cardiovascular disease including:Xx_NEWLINE_xXClinically significant cardiovascular disease at screening including:Xx_NEWLINE_xXSignificant cardiovascular disease including CHF or poorly controlled hypertension.Xx_NEWLINE_xXSignificant cardiovascular disease including CHF or poorly controlled hypertension.Xx_NEWLINE_xXSignificant disease or uncontrolled disease, i.e. cardiovascular renal, hepatic, endocrine, metabolic, neurologic; or other significant disease that would limit the patients ability to participate in the study as determined by the investigator or medical monitor.Xx_NEWLINE_xXunstable cardiovascular functionXx_NEWLINE_xXCurrent severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, thyroid, or metabolic disease; wound healing disorders; ulcers; or bone fractures)Xx_NEWLINE_xXUncontrolled or significant cardiovascular diseaseXx_NEWLINE_xXUncontrolled or significant cardiovascular disease, including:Xx_NEWLINE_xXHistory of certain cardiovascular conditions within the past 6 months.Xx_NEWLINE_xXHistory (within the last 6 months) of significant cardiovascular disease.Xx_NEWLINE_xXSignificant or uncontrolled cardiovascular diseaseXx_NEWLINE_xXSignificant cardiovascular diseaseXx_NEWLINE_xXCurrent severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, or metabolic disease)Xx_NEWLINE_xXHistory of significant cardiovascular disease, defined as:Xx_NEWLINE_xXPrior therapy with known risk for cardiovascular complications.Xx_NEWLINE_xXClinically significant cardiovascular disease.Xx_NEWLINE_xXSignificant cardiovascular diseaseXx_NEWLINE_xXHistory of significant cardiovascular disease will be excludedXx_NEWLINE_xXCurrently active, clinically significant cardiovascular disease or myocardial infarction within 6 months of screeningXx_NEWLINE_xXSignificant history of cardiovascular diseaseXx_NEWLINE_xXClinically significant cardiovascular impairmentXx_NEWLINE_xXImportant cardiovascular events in the past 6 months.Xx_NEWLINE_xXSignificant cardiovascular diseaseXx_NEWLINE_xXHistory or evidence of cardiovascular risk including any of the following:Xx_NEWLINE_xXSubject has a significant cardiovascular diseaseXx_NEWLINE_xXAny of the following cardiovascular conditions:Xx_NEWLINE_xXHistory or presence of clinically relevant cardiovascular abnormalitiesXx_NEWLINE_xXSignificant cardiovascular diseasesXx_NEWLINE_xXSignificant cardiovascular or cerebrovascular disease within 6 months prior to Day 1 of Cycle 1Xx_NEWLINE_xXA history or evidence of cardiovascular risk including any of the following:Xx_NEWLINE_xXImpaired cardiovascular function or clinically significant cardiovascular diseases, including any of the following: symptomatic chronic heart failure; evidence of clinically significant cardiac arrhythmias and/or conduction abnormalities < 6 months prior to screening except atrial fibrillation and paroxysmal supraventricular tachycardiaXx_NEWLINE_xXA history or evidence of cardiovascular risk- specific criteria have to be metXx_NEWLINE_xXCardiovascular abnormalities:Xx_NEWLINE_xXClinically significant cardiovascular riskXx_NEWLINE_xXHistory of serious cardiovascular diseaseXx_NEWLINE_xXClinically significant cardiovascular diseaseXx_NEWLINE_xXSignificant or uncontrolled cardiovascular disease or bleeding disorderXx_NEWLINE_xXPatients with a significant cardiovascular disease or condition, including:Xx_NEWLINE_xXOngoing treatment for pre-existing cardiovascular diseaseXx_NEWLINE_xXEvidence of uncontrolled cardiovascular conditionsXx_NEWLINE_xXCurrent severe, uncontrolled non-cancer systemic disease (e.g., clinically significant cardiovascular, pulmonary, or metabolic disease) resulting in a life expectancy of < 6 monthsXx_NEWLINE_xXA history or evidence of cardiovascular risk including any of the followingXx_NEWLINE_xXPatients with a significant cardiovascular disease or condition, including:Xx_NEWLINE_xXHistory or current condition of uncontrolled cardiovascular diseaseXx_NEWLINE_xXUncontrolled or significant cardiovascular diseaseXx_NEWLINE_xXClinically significant cardiovascular disease including:Xx_NEWLINE_xXUncontrolled or significant cardiovascular diseaseXx_NEWLINE_xXPatients with serious non-malignant disease (e.g. cardiovascular, scleroderma etc.) which would preclude RTXx_NEWLINE_xXCurrent severe, uncontrolled systemic disease (e.g. clinically significant cardiovascular, pulmonary, or metabolic disease; wound healing disorders; ulcers; bone fractures)Xx_NEWLINE_xXUncontrolled hypertension or clinically significant cardiovascular diseaseXx_NEWLINE_xXCurrent severe, uncontrolled systemic disease (including but not limited to clinically significant cardiovascular, pulmonary, or renal disease or ongoing or active infection) excluding the cancer under studyXx_NEWLINE_xXPatients with the following manifestations of cardiovascular disease are excluded:Xx_NEWLINE_xXEvidence of current uncontrolled cardiovascular conditionsXx_NEWLINE_xXHistory of certain cardiovascular conditions within the past 6 months.Xx_NEWLINE_xXSignificant cardiovascular impairment, defined as:Xx_NEWLINE_xXNon-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude any of the study drugsXx_NEWLINE_xXImpaired cardiovascular function or clinically significant cardiovascular diseasesXx_NEWLINE_xXPatient has uncontrolled or significant cardiovascular disease, including:Xx_NEWLINE_xXNo unstable neurologic, hepatic, renal, cardiovascular, lymphatic, or metabolic diseaseXx_NEWLINE_xXEvidence of clinically significant disease (e.g., cardiovascular, respiratory, gastrointestinal, renal, or infectious disease) that in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessmentsXx_NEWLINE_xXUncontrolled or significant cardiovascular diseaseXx_NEWLINE_xXCardiovascular diseaseXx_NEWLINE_xXPatients with malnutrition, active infection, significant pulmonary disease and cardiovascular disease as determined by the physician as they could impact fatigueXx_NEWLINE_xXUnstable cardiovascular disease in the last 6 monthsXx_NEWLINE_xXUncontrolled or significant cardiovascular disease, including any of the following:Xx_NEWLINE_xXHistory of clinically-significant cardiovascular diseaseXx_NEWLINE_xXSignificant history of cardiovascular diseaseXx_NEWLINE_xXAny history of cardiovascular, kidney, or liver diseaseXx_NEWLINE_xXSevere cardiovascular, pulmonary or other systemic conditions that prevent participation in the studyXx_NEWLINE_xXAny prior cardiovascular diseaseXx_NEWLINE_xXA history of cardiovascular disease, hypertension, or peripheral arterial/vascular disease;Xx_NEWLINE_xXA cardiovascular event in the past monthXx_NEWLINE_xXUntreated or uncontrolled cardiovascular disease or other symptomatic cardiac dysfunctionXx_NEWLINE_xXHistory of clinically significant cardiovascular disease, gastrointestinal disorder, or significant pulmonary compromise.Xx_NEWLINE_xXPatients with known significant active cardiovascular or pulmonary disease at the time of study entry are ineligibleXx_NEWLINE_xXSignificant cardiovascular diseaseXx_NEWLINE_xXunstable pulmonary or cardiovascular conditions.Xx_NEWLINE_xXNot be undergoing evaluation and workup for active cardiovascular disease; men with treated and stable cardiovascular disease may participateXx_NEWLINE_xXAcute major illness (e.g., unstable cardiovascular condition, etc.)Xx_NEWLINE_xXAcute major illness (e.g., unstable cardiovascular condition, etc.)Xx_NEWLINE_xXAcute major illness (e.g. unstable cardiovascular condition, etc.)Xx_NEWLINE_xXSignificant cardiovascular disease including CHF or poorly controlled hypertension.Xx_NEWLINE_xXActive, unstable cardiovascular function:Xx_NEWLINE_xXHistory of clinically significant cardiovascular diseaseXx_NEWLINE_xXHave any of the following cardiovascular conditions:Xx_NEWLINE_xXUncontrolled or significant cardiovascular diseaseXx_NEWLINE_xXClinically significant cardiac/cardiovascular disease, or pulmonary compromiseXx_NEWLINE_xXClinically significant cardiovascular disease including:Xx_NEWLINE_xXCurrently active clinically significant cardiovascular disease or history of myocardial infarction within 6 months of first doseXx_NEWLINE_xX